Skip to main navigation Skip to search Skip to main content

Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study

  • Yusuke Iwata
  • , Shinichiro Nakajima
  • , Eric Plitman
  • , Fernando Caravaggio
  • , Julia Kim
  • , Parita Shah
  • , Wanna Mar
  • , Sofia Chavez
  • , Vincenzo De Luca
  • , Masaru Mimura
  • , Gary Remington
  • , Philip Gerretsen
  • , Ariel Graff-Guerrero

Research output: Contribution to journal › Article › peer-review

Abstract

Background: In terms of antipsychotic treatment response, patients with schizophrenia can be classified into three groups: 1) treatment resistant to both non-clozapine (non-CLZ) antipsychotics and CLZ (ultra-treatment-resistant schizophrenia [URS]), 2) treatment resistant to non-CLZ antipsychotics but CLZ-responsive schizophrenia [non-URS]), and 3) responsive to first-line antipsychotics (non-treatment-resistant schizophrenia). This study aimed to compare glutamatergic neurometabolite levels among these three patient groups and healthy control subjects using proton magnetic resonance spectroscopy. Methods: Glutamate and glutamate+glutamine levels were assessed in the caudate, the dorsal anterior cingulate cortex (dACC), and the dorsolateral prefrontal cortex using 3T proton magnetic resonance spectroscopy (point-resolved spectroscopy, echo time = 35 ms). Glutamatergic neurometabolite levels were compared between the groups. Results: A total of 100 participants were included, consisting of 26 patients with URS, 27 patients with non-URS, 21 patients with non-treatment-resistant schizophrenia, and 26 healthy control subjects. Group differences were detected in ACC glutamate+glutamine levels (F 3,96 = 2.93, p =.038); patients with URS showed higher dACC glutamate+glutamine levels than healthy control subjects (p =.038). There were no group differences in the caudate or dorsolateral prefrontal cortex. Conclusions: Taken together with previous studies that demonstrated higher ACC glutamate levels in patients with treatment-resistant schizophrenia, this study suggests that higher levels of ACC glutamatergic metabolites may be among the shared biological characteristics of treatment resistance to antipsychotics, including CLZ.

Original languageEnglish
Pages (from-to)596-605
Number of pages10
JournalBiological Psychiatry
Volume85
Issue number7
DOIs
Publication statusPublished - 2019 Apr 1

Keywords

  • Antipsychotic
  • Clozapine
  • Glutamate
  • H-MRS
  • Schizophrenia
  • Treatment-resistant

ASJC Scopus subject areas

  • Biological Psychiatry

Fingerprint

Dive into the research topics of 'Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study'. Together they form a unique fingerprint.

Cite this